Mixed immunotherapy and chemotherapy of tumors: Modeling, applications and biological interpretations

Journal of Theoretical Biology

Volumn 238, Issue 4, 2006, Pages 841-862

  De Pillis, L G ^a   Gu, W ^a   Radunskaya, A E ^b  

^a HARVEY MUDD COLLEGE   (United States)

^b POMONA COLLEGE   (United States)

Author keywords

Cancer; Chemotherapy; Immunotherapy; Mathematical modeling; Tumor; Vaccine

Indexed keywords

CANCER VACCINE;

CANCER;

ARTICLE; BIOLOGICAL MODEL; CANCER CELL; CANCER CHEMOTHERAPY; CANCER GROWTH; CD8+ T LYMPHOCYTE; CELL POPULATION; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOTHERAPY; LYMPHOCYTE; MATHEMATICAL ANALYSIS; MATHEMATICAL MODEL; MULTIMODALITY CANCER THERAPY; NATURAL KILLER CELL; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; SIMULATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; COMBINED MODALITY THERAPY; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-2; MICE; MODELS, BIOLOGICAL; NEOPLASMS;

EID: 31744436379     PISSN: 00225193     EISSN: 10958541     Source Type: Journal    
DOI: 10.1016/j.jtbi.2005.06.037     Document Type: Article

References (93)

1. Adam, J.A., Bellomo, N. (Eds.), 1997. A Survey of Models for Tumor-Immune System Dynamics, Chapter, Basic Models of Tumor-Immune System Interactions - Identification, Analysis and Predictions. Birkhauser, Basel.
2. P.A. Antony, and N.P. Restifo CD4+CD25+ T regulatory cells, immunotherapy of cancer, and interleukin-2 J. Immunother 28 2 2005 120 128
3. Bannock, L., 2002. Nutrition. Found at http://www.doctorbannock.com/ nutrition.html.
4. N. Bellomo, and L. Preziosi Modelling and mathematical problems related to tumor evolution and its interaction with the immune system Math. Comput. Model. 32 2000 413 452
5. N. Bellomo, A. Bellouquid, and M. Delitala Mathematical topics on the modelling of multicellular systems in competition between tumor and immune cells Math. Mod. Meth. Appl. S. 14 2004 1683 1733
6. J.N. Blattman, and P.D. Greenberg Cancer immunotherapy: a treatment for the masses Science 305 2004 200 205
7. N.F. Britton Essential Mathematical Biology 2003 Springer Berlin
8. Calabresi, P., Schein, P.S. (Eds.), 1993. Medical Oncology: Basic Principles and Clinical Management of Cancer, second ed. McGraw-Hill, New York.
9. Cancer Research Institute, 2000. Cancer and the immune system: the vital connection. Web page publication of the Cancer Research Institute, available at http://www.cancerresearch.org/immunology/immuneindex.html, accessed May 2005.
10. R.Y. Chandawarkar, and D.P. Guyton Oncologic mathematics - evolution of a new specialty Arch. Surg. 137 2002 1428 1434
11. K.A. Chester, A. Mayer, J. Bhatia, L. Robson, D.I.R. Spencer, S.P. Cooke, A.A. Flynn, S.K. Sharma, G. Boxer, R.B. Pedley, and R.H.J. Begent Recombinant anti-carcinoembryonic antigen antibodies for targeting cancer Cancer Chemother. Pharmacol. 46 2000 S8 S12
12. M.A. Cooper, T.A. Fehniger, and M.A. Caligiuri The biology of human natural killer-cell subsets Trends Immunol. 22 11 2001 633 640
13. J. Couzin Select T cells, given space, shrink tumors Science 297 2002 1973
14. S.B. Cui Analysis of a mathematical model for the growth of tumors under the action of external inhibitors J. Math. Biol. 44 2002 395 426
15. B. Curti, A. Ochoa, W. Urba, G. Alvord, W. Kopp, G. Powers, C. Hawk, S. Creekmore, B. Gause, J. Janik, J. Holmlund, P. Kremers, R. Fenton, L. Miller, M. Sznol, J. Smith II, W. Sharfman, and D. Longo Influence of interleukin-2 regimens on circulating populations of lymphocytes after adoptive transfer of anti-CD3-stimulated T cells: results from a phase I trial in cancer patients J. Immunother. Emphasis Tumor Immunol. 19 4 1996 296 308
16. A. Dalgleish The relevance of non-linear mathematics (chaos theory) to the treatment of cancer, the role of the immune response and the potential for vaccines QJM 92 1999 347 359
17. A.G. Dalgleish, and K.J. O'Byrne Chronic immune activation and inflammation in the pathogenesis of AIDS and cancer Adv. Cancer Res. 84 2002 231 276
18. E. De Angelis, and P.E. Jabin Qualitative analysis of a mean field model of tumor-immune system competition Math. Mod. Meth. Appl. S. 13 2003 187 206
19. E. De Angelis, and L. Mesin Modelling of the immune response: conceptual frameworks and applications Math. Mod. Meth. Appl. S. 11 2001 1609 1630
20. R.J. de Boer, and P. Hogeweg Interactions between macrophages and T-lymphocytes: tumor sneaking through intrinsic to helper T cell dynamics J. Theor. Biol. 120 3 1986 331 351
21. M. Delitala Critical analysis and perspectives on kinetic (cellular) theory of immune competition Math. Comput. Model. 35 2002 63 75
22. L.G. de Pillis, and A.E. Radunskaya A mathematical tumor model with immune resistance and drug therapy: an optimal control approach J. Theor. Med. 3 2001 79 100
23. L.G. de Pillis, and A.E. Radunskaya The dynamics of an optimally controlled tumor model: a case study Math. Comput. Model. 37 2003 1221 1244
24. L.G. de Pillis, and A.E. Radunskaya Immune response to tumor invasion K. Bathe Computational Fluid and Solid Mechanics vol. 2 2003 MIT Press Cambridge, MA 1661 1668
25. de Pillis, L.G., Radunskaya, A.E., Wiseman, C.L., 2003. A validated mathematical model of cell-mediated immune responses to tumor invasion and vaccine therapy in mice and humans, invited Poster, Society of Biological Therapy 17th Annual Meeting.
26. L. Derbel Analysis of a new model for tumor-immune system competition including long time scale effects Math. Mod. Meth. Appl. S. 14 2004 1657 1681
27. A. Diefenbach, E.R. Jensen, A.M. Jamieson, and D. Raulet Rae1 and H60 ligands of the NKG2D receptor stimulate tumor immunity Nature 413 2001 165 171
28. J. Donnelly Cancer vaccine targets leukemia Nat. Med. 9 11 2003 1354 1356
29. M.E. Dudley, J.R. Wunderlich, P.F. Robbins, J.C. Yang, P. Hwu, D.J. Schwartzentruber, S.L. Topalian, R. Sherry, N.P. Restifo, A.M. Hubicki, M.R. Robinson, M. Raffeld, P. Duray, C.A. Seipp, L. Rogers-Freezer, K.E. Morton, S.A. Mavroukakis, D.E. White, and S.A. Rosenberg Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes Science 298 5594 2002 850 854
30. J.D. Farrar, K.H. Katz, J. Windsor, G. Thrush, R.H. Scheuermann, J.W. Uhr, and N.E. Street Cancer dormancy. VII. A regulatory role for CD8+ T cells and IFN-gamma in establishing and maintaining the tumor-dormant state J. Immunol. 162 5 1999 2842 2849
31. S.C. Ferreira, M.L. Martins, and M.J. Vilela Reaction-diffusion model for the growth of avascular tumor Phys. Rev. E 65 2002
32. S.W. Friedrich, S.C. Lin, B.R. Stoll, L.T. Baxter, L.L. Munn, and R.K. Jain Antibody-directed effector cell therapy of tumors: analysis and optimization using a physiologically based pharmacokinetic model Neoplasia 4 2002 449 463
33. P. Garcia-Penarrubia, N. Lorenzo, J. Galvez, A. Campos, X. Ferez, and G. Rubio Study of the physical meaning of the binding parameters involved in effector-target conjugation using monoclonal antibodies against adhesion molecules and cholera toxin Cell Immunol. 215 2002 141 150
34. S.N. Gardner A mechanistic, predictive model of dose-response curves for cell cycle phase-specific and nonspecific drugs Cancer Res. 60 2000 1417 1425
35. R.A. Gatenby, and E.T. Gawlinski The glycolytic phenotype in carcinogenesis and tumor invasion: insights through mathematical models Cancer Res. 63 2003 3847 3854
36. R.A. Gatenby, and P.K. Maini Modelling a new angle on understanding cancer Nature 410 2002 462
37. R.A. Gatenby, and T.L. Vincent Application of quantitative models from population biology and evolutionary game theory to tumor therapeutic strategies Mol. Cancer Ther. 2 9 2003 919 927
38. R.N. Germain An innately interesting decade of research in immunology Nat. Med. 10 12 2004 1307 1320
39. A. Gett, F. Sallusto, A. Lanzavecchia, and J. Geginat T cell fitness determined by signal strength Nat. Immunol. 4 4 2003 355 360
40. S.M. Gilbertson, P.D. Shah, and D.A. Rowley NK cells suppress the generation of Lyt-2+ cytolytic T cells by suppressing or eliminating dendritic cells J. Immunol. 136 10 1986 3567 3571
41. R. Glas, L. Franksson, C. Une, M. Eloranta, C. Ohlen, A. Orn, and K. Karre Recruitment and activation of natural killer (NK) cells in vivo determined by the target cell phenotype: an adaptive component of NK cell-mediated responses J. Exp. Med. 191 1 2000 129 138
42. T.A. Hadj Alemtuzumab for B-cell chronic lymphocytic leukemia Issues Emerg. Health Technol. 66 2005 1 4
43. I. Hara, H. Hotta, N. Sato, H. Eto, S. Arakawa, and S. Kamidono Rejection of mouse renal cell carcinoma elicited by local secretion of interleukin-2 Jpn. J. Cancer Res. 87 7 1996 724 729
44. K. Hardy, and J. Stark Mathematical models of the balance between apoptosis and proliferation Apoptosis 7 2002 373 381
45. Hauser, B., 2001. Blood tests. Technical Report, International Waldenstrom's Macroglobulinemia Foundation. Available at http://www.iwmf.com/ Blood_Tests.pdf, accessed May 2005.
46. Holland, J.F., Emil III, F. (Eds.), 1973. Cancer Medicine. Lea and Febiger (Chapter II-3, XII, XV).
47. A.Y.C. Huang, P. Golumbek, M. Ahmadzadeh, E. Jaffee, D. Pardoll, and H. Levitsky Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens Science 264 5161 1994 961 965
48. H. Jiang, and L. Chess An integrated view of suppressor T cell subsets in immunoregulation J. Clin. Invest. 114 9 2004 1198 1208
49. Y. Kawarada, R. Ganss, N. Garbi, B. Sacher, T. ad Arnold, and G. Hammerling NK- and CD8+T cell-mediate eradication of established tumors by peritumoral injection of CpG-containing oligodeoxynucleotides J. Immunol. 167 1 2001 5247 5253
50. D. Keil, R.W. Luebke, and S.B. Pruett Quantifying the relationship between multiple immunological parameters and host resistance: probing the limits of reductionism J. Immunol. 167 2001 4543 4552
51. W.C. Kieper, M. Prlic, C.S. Schmidt, M.F. Mescher, and S.C. Jameson Il-12 enhances CD8 T cell homeostatic expansion J. Immunol. 166 2001 5515 5521
52. D. Kirschner, and J.C. Panetta Modeling immunotherapy of the tumor-immune interaction J. Math. Biol. 37 3 1998 235 252
53. M. Kolev Mathematical modelling of the competition between tumors and immune system considering the role of the antibodies Math. Comput. Model. 37 2003 1143 1152
54. V. Kuznetsov, and I. Makalkin Bifurcation-analysis of mathematical-model of interactions between cytotoxic lymphocytes and tumor-cells - effect of immunological amplification of tumor-growth and its connection with other phenomena of oncoimmunology Biofizika 37 6 1992 1063 1070
55. V. Kuznetsov, I. Makalkin, M. Taylor, and A. Perelson Nonlinear dynamics of immunogenic tumors: parameter estimation and global bifurcation analysis Bull. Math. Biol. 56 2 1994 295 321
56. V.A. Kuznetsov, and G.D. Knott Modeling tumor regrowth and immunotherapy Math. Comput. Model. 33 2001 1275 1287
57. A. Lanzavecchia, and F. Sallusto Dynamics of T-lymphocyte responses: intermediates, effectors, and memory cells Science 290 2000 92 97
58. J. Li, K. Guo, V.W. Koh, J.P. Tang, B.Q. Gan, H. Shi, H.X. Li, and Q. Zeng Generation of PRL-3- and PRL-1-specific monoclonal antibodies as potential diagnostic markers for cancer metastases Clin. Cancer Res. 11 6 2005 2195 2204
59. U. Lucia, and G. Maino Thermodynamical analysis of the dynamics of tumor interaction with the host immune system Physica A 313 2002 569 577 10.1016/S0378-4371(02)00980-9
60. A. Lumsden, J. Codde, P. Van Der Meide, and B. Gray Immunohistochemical characterisation of immunological changes at the tumour site after chemo-immunotherapy with doxorubicin, interleukin-2 and interferon-γ Anticancer Res. 167 7 1996 1145 1154
61. J. Machiels, R.T. Reilly, L.A. Emens, A.M. Ercolini, R.Y. Lei, D. Weintraub, F.I. Okoye, and E.M. Jaffee Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage- colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice Cancer Res. 61 9 2001 3689 3697
62. F.M. Marincola, E. Wang, M. Herlyn, B. Seliger, and S. Ferrone Tumors as elusive targets of T-cell-based active immunotherapy Trends Immunol. 24 2003 335 342
63. B. Melichar, J. Dvorak, P. Jandik, M. Touskova, D. Solichova, J. Megancova, and Z. Voboril Intraarterial chemotherapy of malignant melanoma metastatic to the liver Hepatogastroenterology 48 42 2001 1711 1715
64. S. Morecki, T. Pugatsch, S. Levi, Y. Moshel, and S. Slavin Tumor-cell vaccination induces tumor dormancy in a murine model of B-cell leukemia/lymphoma (BCL1) Int. J. Cancer 65 2 1996 204 208
65. M. Muller, F. Gounari, S. Prifti, H.J. Hacker, V. Schirrmacher, and K. Khazaie EblacZ tumor dormancy in bone marrow and lymph nodes: active control of proliferating tumor cells by CD8+ immune T cells Cancer Res. 58 23 1998 5439 5446
66. M.M. Mustafa, G.R. Buchanan, N.J. Winick, G.H. McCracken, I. Tkaczewski, M. Lipscomb, Q. Ansari, and M.S. Agopian Immune recovery in children with malignancy after cessation of chemotherapy J. Pediatr. Hematol. Oncol. 20 5 1998 451 457
67. F. Nani, and H.I. Freedman A mathematical model of cancer treatment by immunotherapy Math. Biosci. 163 2000 159 199
68. National Cancer Institute, 2005. National cancer institute clinical trials web site. Available at http://www.nci.nih.gov/clinicaltrials, accessed May 2005.
69. National Cancer Institute, 2005. Understanding chemotherapy. Available at http://www.nci.nih.gov/cancertopics/chemotherapy-and-you/page2, accessed May 2005.
70. K.J. O'Byrne, A.G. Dalgleish, M.J. Browning, W.P. Steward, and A.L. Harris The relationship between angiogenesis and the immune response in carcinogenesis and the progression of malignant disease Eur. J. Cancer 36 2000 151 169
71. T. Osada, H. Nagawa, and Y. Shibata Tumor-infiltrating effector cells of α-galactosylceramide-induced antitumor immunity in metastatic liver tumor J. Immune Based Ther. Vaccines 2 7 2004 1 9
72. M.R. Owen, and J.A. Sherratt Mathematical modelling of macrophage dynamics in tumours Math. Mod. Meth. Appl. S. 9 1999 513 539
73. D.M. Pardoll Cancer vaccines Nat. Med. 4 5 1998 525 531
74. Pazdur, R., Hoskins, W., Wagman, L., Coia, L. (Eds.), 2004. Cancer Management: A Mulitdisciplinary Approach. Chapter: Principles of Chemotherapy, eighth ed. Oncology Publishing Group of CMP Healthcare Media. Available at http://www.cancernetwork.com/handbook/contents.htm, accessed May 2005.
75. A.S. Perelson, and G. Weisbuch Immunology for physicists Rev. Mod. Phys. 69 4 1997 1219 1267
76. Perry, M.C. (Ed.), 2001. The Chemotherapy Source Book, third ed. Lippincott Williams & Wilkins.
77. Z. Qu, G.L. Griffiths, W.A. Wegener, C.H. Chang, S.V. Govindan, I.D. Horak, H.J. Hansen, and D.M. Goldenberg Development of humanized antibodies as cancer therapeutics Methods 36 1 2005 84 95 10.1016/j.ymeth.2005.01.008
78. I.M. Roitt, J. Brostoff, and D.K. Male Immunology 1993 Mosby St. Louis
79. E. Rosenbaum, and I. Rosenbaum Everyone's Guide to Cancer Supportive Care: A Comprehensive Handbook for Patients and Their Families 2005 Andrews McMeel Publishing
80. S. Rosenberg, and M. Lotze Cancer immunotherapy using interleukin-2 and interleukin-2-activated lymphoytes Annu. Rev. Immunol. 4 1986 681 709
81. S.A. Rosenberg, J.C. Yang, and N.P. Restifo Cancer immunotherapy: moving beyond current vaccines Nat. Med. 10 9 2004 909 915
82. Sotolongo-Costa, O., Molina, L.M., Perez, D.R., Antoranz, J.C., Reyes, M.C., 2003. Behavior of tumors under nonstationary therappy. Physica D 178, 242-253 doi.org/10.1016/S0167-2789(03)00005-8.
83. O. Sotolongo-Costa, L.M. Molina, D.R. Perez, J.C. Antoranz, and M.C. Reyes Behavior of tumors under nonstationary therapy Physica D 178 2003 242 253 10.1016/S0167-2789(03)00005-8
84. R.F. Stengel, R. Ghigliazza, N. Kulkarni, and O. Laplace Optimal control of innate immune response Optim. Contr. Appl. Met. 23 2002 91 104
85. T.H. Stewart Immune mechanisms and tumor dormancy Medicina - Buenos Aire 56 1 1996 74 82
86. T. Takayanagi, and A. Ohuchi A mathematical analysis of the interactions between immunogenic tumor cells and cytotoxic t lymphocytes Microbiol. Immunol. 45 2001 709 715
87. R. Wallace, D. Wallace, and R.G. Wallace Toward cultural oncology: the evolutionary information dynamics of cancer Open. Syst. Inf. Dyn. 10 2003 159 181
88. S.D. Webb, J.A. Sherratt, and R.G. Fish Cells behaving badly: a theoretical model for the Fas/FasL system in tumour immunology Math. Biosci. 179 2002 113 129
89. L.M. Wein, J.T. Wu, and D.H. Kirn Validation and analysis of a mathematical model of a replication-competent oncolytic virus for cancer treatment: implications for virus design and delivery Cancer Res. 63 2003 1317 1324
90. C.J. Wheeler, D. Asha, L. Gentao, J.S. Yu, and K.L. Black Clinical responsiveness of glioblastoma multiforme to chemotherapy after vaccination Clin. Cancer Res. 10 2004 5316 5326
91. D. Wodarz Viruses as antitumor weapons: defining conditions for tumor remission Cancer Res. 61 2001 3501 3507
92. D. Wodarz, and V.A.A. Jansen A dynamical perspective of ctl cross-priming and regulation: implications for cancer immunology Immunol. Lett. 86 2003 213 227
93. A. Yates, and R. Callard Cell death and the maintenance of immunological memory Discrete Contin. Dyn. S. 1 1 2002 43 59